- Home
- TEVA vs XYL Comparison
TEVA vs XYL Comparison
Compare TEVA & XYL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TEVA | XYL |
|---|---|---|
| Founded | 1901 | 2011 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Fluid Controls |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.2B | 31.5B |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | TEVA | XYL |
|---|---|---|
| Price | $33.65 | $131.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 10 |
| Target Price | $37.25 | ★ $157.89 |
| AVG Volume (30 Days) | ★ 7.8M | 1.8M |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | ★ 1.30% |
| EPS Growth | N/A | ★ 7.40 |
| EPS | N/A | ★ 3.92 |
| Revenue | N/A | ★ $9,035,000,000.00 |
| Revenue This Year | N/A | $2.84 |
| Revenue Next Year | $2.97 | $4.51 |
| P/E Ratio | ★ $28.19 | $33.51 |
| Revenue Growth | N/A | ★ 5.52 |
| 52 Week Low | $12.47 | $100.47 |
| 52 Week High | $37.35 | $154.27 |
Technical Indicators
Market Signals| Indicator | TEVA | XYL |
|---|---|---|
| Relative Strength Index (RSI) | 51.67 | 45.84 |
| Support Level | $30.70 | $130.33 |
| Resistance Level | $35.32 | $133.31 |
| Average True Range (ATR) | 0.80 | 3.58 |
| MACD | -0.23 | -0.03 |
| Stochastic Oscillator | 18.07 | 38.89 |
Price Performance
Historical ComparisonAbout TEVA Teva Pharmaceutical Industries Limited
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
About XYL Xylem Inc. New
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $9 billion in revenue in 2025.